Ultromics Partners for Faster Development of Echo AI Algorithm for Early Cardiac Amyloidosis Detection

Friday, January 12, 2024

Ultromics, a health technology company rooted in the University of Oxford, UK, has entered into a collaboration with Pfizer to validate and seek FDA clearance for its AI-driven technology aimed at detecting cardiac amyloidosis. This condition often goes unnoticed in standard assessments, and Ultromics' EchoGo® Amyloidosis algorithm, already granted Breakthrough Device Designation, utilizes deep learning to analyze routine ultrasound scans of the heart (echocardiograms) for early detection.

While echocardiography is essential for identifying various heart conditions early on, challenges such as subjectivity and the need for specialized expertise in identifying cardiac amyloidosis accurately exist. The partnership with Pfizer aims to support Ultromics in obtaining FDA clearance for its AI algorithm, potentially improving the early detection of cardiac amyloidosis through routine ultrasound scans. Early identification is crucial for this condition, as optimal treatments are often more effective when implemented early in its progression.

The FDA's Breakthrough Device Designation recognizes the algorithm's potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases. The collaboration between Ultromics and Pfizer signifies a step forward in advancing AI-driven healthcare technologies, particularly in enhancing the early detection of cardiac amyloidosis, even in clinical settings with limited time and resources for comprehensive assessments.


Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital Congress